Wedbush Research Analysts Increase Earnings Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities research analysts at Wedbush upped their FY2026 EPS estimates for shares of Travere Therapeutics in a research report issued on Wednesday, October 9th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $2.81 per share for the year, up from their prior estimate of $2.28. Wedbush has a “Outperform” rating and a $25.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.95) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2027 earnings at $3.83 EPS and FY2028 earnings at $3.92 EPS.

TVTX has been the subject of a number of other reports. Guggenheim lifted their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group dropped their price objective on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, September 30th. JPMorgan Chase & Co. lifted their price objective on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Citigroup dropped their price objective on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, September 27th. Finally, Leerink Partners reissued an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $19.75.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $16.41 on Friday. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $18.60. The stock has a market capitalization of $1.26 billion, a P/E ratio of -8.73 and a beta of 0.73. The firm has a fifty day simple moving average of $11.78 and a two-hundred day simple moving average of $8.97. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million during the quarter, compared to the consensus estimate of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%.

Insider Activity at Travere Therapeutics

In related news, insider Jula Inrig sold 2,191 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $25,240.32. Following the completion of the sale, the insider now owns 62,633 shares in the company, valued at $721,532.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Jula Inrig sold 2,191 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $25,240.32. Following the completion of the sale, the insider now owns 62,633 shares in the company, valued at $721,532.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP William E. Rote sold 4,387 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $50,538.24. Following the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at $972,921.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,707 shares of company stock worth $1,504,312 in the last 90 days. 3.75% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Travere Therapeutics

Several large investors have recently modified their holdings of the business. Creative Planning raised its holdings in shares of Travere Therapeutics by 4.3% in the 3rd quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after purchasing an additional 995 shares in the last quarter. Forefront Analytics LLC raised its holdings in shares of Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Travere Therapeutics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after acquiring an additional 1,557 shares in the last quarter. Rice Hall James & Associates LLC raised its stake in shares of Travere Therapeutics by 3.8% during the 2nd quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company’s stock worth $626,000 after acquiring an additional 2,774 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Travere Therapeutics by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock worth $240,000 after acquiring an additional 2,948 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.